The Spinal Muscular Atrophy Medicine Market study by Company, Region, Type, Material, and Application; offered by Stratview Research discusses the most up-to-date market trends as well as an industry growth estimate for the next 5 years. The report covers industry profiles of key players, including market share, regional analysis, and market division, business development strategies, mergers acquisitions, alliances, and key financial data, etc.

Market Insights

According to the report, the Spinal Muscular Atrophy Medicine Market is projected to grow from USD 980.6 million in 2020 to USD 2,085.4 million by 2026 at a CAGR of 13.4% during the forecast period.

What is spinal muscular atrophy (SMA)?

Spinal Muscular Atrophy (SMA) is a very rare genetic disorder that affects the part of the central nervous system that controls voluntary muscle movements. SMA is an autosomal recessive neurodegenerative genetic disorder that is characterized by atrophy and the weakening of muscles. It is one of the most common debilitating genetic disorders and a primary genetic cause of death among infants. It mainly affects approximately one in 10,000 live births across the globe.

Market Dynamics

Rising incidence and awareness for spinal muscular atrophy has surged significantly which is likely to spur the need for efficient therapeutic options, resulting in better patient outcomes.

Growing awareness regarding SMA worldwide and a rising number of initiatives to enhance the treatment options for such rare diseases are some of the prime factors bolstering the SMA medicine demand.

Also, favourable initiatives undertaken by the government, public, and non-profit organizations for spreading awareness regarding SMA are further augmenting the market growth.

However, the high cost associated with SMA treatment and medicines is likely to hinder the industry's growth.

Key Players

The following are the key players in the Spinal Muscular Atrophy Medicine Market -

Biogen (The U.S),

Ionis Pharmaceuticals, Inc. (The U.S),

Hoffmann - La Roche Ltd (Switzerland),

Avexis, Inc. (The U.S),

Novartis AG (Switzerland),

Cytokinetics, Inc. (The U.S),

Pfizer Inc. (The U.S),

Boehringer Ingelheim International GmbH (Germany),

Regeneron Pharmaceuticals, Inc (The U.S), and

Abbott (The U.S).

Research Methodology

This market report from Stratview Research provides a thorough analysis that reflects present and future market possibilities for the forecast period of 2021 to 2026. This market report is compiled through several authenticated secondary sources, such as the company’s annual reports, press releases, white papers, articles, etc. Also, the market experts have performed several interviews with the industry stakeholders in order to collect reliable and insightful information.

Custom Research:

Stratview Research delivers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry to [email protected]

Critical Questions Answered in the Report

What are the key trends in the Spinal Muscular Atrophy Medicine Market?

How has the market (and its various sub-segments) grown in the last five years?

What would be the growth rate in the next five years?

What is the impact of COVID-19 on the market?

What are the key strategies adopted by the major vendors to lead in the Spinal Muscular Atrophy Medicine Market?

What is the market share of the top vendors?

About Us

Stratview Research is a global market research firm helping its users tract the ever-evolving market scenarios through its top-notch market reports. It offers the most granular market segmentation across all industries. Connect with Stratview Research, for any queries at –

E-mail: [email protected] Direct: +1-313-307-4176